Reasons for low uptake of a psychological intervention offered to cancer survivors with elevated depressive symptoms.
Loek J van der Donk, K Annika Tovote, Thera P Links, Jan L N Roodenburg, Johanna C Kluin-Nelemans, Henriette J G Arts, Veronique E M Mul, Robert J van Ginkel, Peter C Baas, Christiaan Hoff, Robbert Sanderman, Joke Fleer, Maya J Schroevers
Author Information
Loek J van der Donk: Department of Health Psychology University of Groningen, University Medical Center Groningen, Groningen, the Netherlands. ORCID
K Annika Tovote: Department of Health Psychology University of Groningen, University Medical Center Groningen, Groningen, the Netherlands. ORCID
Thera P Links: Department of Endocrinology and Metabolic Diseases University of Groningen, University Medical Center Groningen, Groningen, the Netherlands. ORCID
Jan L N Roodenburg: Department of Oral and Maxillofacial Surgery, Section of Oncology University of Groningen, University Medical Center Groningen, Groningen, the Netherlands.
Johanna C Kluin-Nelemans: Department of Haematology, University of Groningen, University Medical Center Groningen Groningen, Groningen, the Netherlands. ORCID
Henriette J G Arts: Department of Obstetrics and Gynecology, University of Groningen, University Medical Center Groningen, Groningen, the Netherlands.
Veronique E M Mul: Department of Radiation Oncology, University of Groningen, University Medical Center Groningen, the Netherlands. ORCID
Robert J van Ginkel: Department of Surgery, Laboratory for Translational Surgical Oncology, University of Groningen, University Medical Center Groningen, Groningen, the Netherlands.
Peter C Baas: Department of Surgery, Martini Hospital, Groningen, the Netherlands.
Christiaan Hoff: Department of Surgery, Medical Center Leeuwarden, Leeuwarden, the Netherlands.
Robbert Sanderman: Department of Health Psychology University of Groningen, University Medical Center Groningen, Groningen, the Netherlands. ORCID
Joke Fleer: Department of Health Psychology University of Groningen, University Medical Center Groningen, Groningen, the Netherlands.
Maya J Schroevers: Department of Health Psychology University of Groningen, University Medical Center Groningen, Groningen, the Netherlands. ORCID
OBJECTIVE: In line with screening guidelines, cancer survivors were consecutively screened on depressive symptoms (as part of standard care), with those reporting elevated levels of symptoms offered psychological care as part of a trial. Because of the low uptake, no conclusions could be drawn about the interventions' efficacy. Given the trial set-up (following screening guidelines and strict methodological quality criteria), we believe that this observational study reporting the flow of participation, reasons for and characteristics associated with nonparticipation, adds to the debate about the feasibility and efficiency of screening guidelines. METHODS: Two thousand six hundred eight medium- to long-term cancer survivors were consecutively screened on depressive symptoms using the Patient Health Questionnaire-9 (PHQ-9). Those with moderate depressive symptoms (PHQ-9 ≥ 10) were contacted and informed about the trial. Patient flow and reasons for nonparticipation were carefully monitored. RESULTS: One thousand thirty seven survivors (74.3%) returned the questionnaire, with 147 (7.6%) reporting moderate depressive symptoms. Of this group, 49 survivors (33.3%) were ineligible, including 26 survivors (17.7%) already receiving treatment and another 44 survivors (30.0%) reporting no need for treatment. Only 25 survivors (1.0%) participated in the trial. CONCLUSION: Of the approached survivors for screening, only 1% was eligible and interested in receiving psychological care as part of our trial. Four reasons for nonparticipation were: nonresponse to screening, low levels of depressive symptoms, no need, or already receiving care. Our findings question whether to spend the limited resources in psycho-oncological care on following screening guidelines and the efficiency of using consecutive screening for trial recruitment in cancer survivors.